We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+51.52%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$361M
AUM Growth
+$93.2M
Cap. Flow
+$8.94M
Cap. Flow %
2.48%
Top 10 Hldgs %
42.47%
Holding
67
New
20
Increased
17
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$9.16M
2
ASND icon
Ascendis Pharma A/S
ASND
+$8.32M
3
NVTA
Invitae Corporation
NVTA
+$7.76M
4
OCUL icon
Ocular Therapeutix
OCUL
+$7.64M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.14M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$24.5M
2
BPMC
Blueprint Medicines
BPMC
+$12.6M
3
AMRN
Amarin Corp
AMRN
+$10.9M
4
XNCR icon
Xencor
XNCR
+$6.51M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$5.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Miscellaneous 0.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDXS icon
1
Codexis
CDXS
$182M
$30.3M 8.39%
1,475,000
-275,000
-16% -$5.34M
AXGN icon
2
Axogen
AXGN
$2.78B
$23.2M 6.41%
1,100,000
-200,000
-15% -$3.65M
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$16.9M 4.68%
1,365,000
+240,000
+21% +$2.68M
AVTX icon
4
Avalo Therapeutics
AVTX
$1.08B
$13.4M 3.72%
799
+40
+5% +$598K
AMRN
5
Amarin Corp
AMRN
$297M
$13.4M 3.71%
32,250
-30,250
-48% -$10.9M
QURE icon
6
uniQure
QURE
$3.44B
$12.2M 3.39%
+205,000
New +$9.16M
ASND icon
7
Ascendis Pharma A/S
ASND
$16.4B
$11.2M 3.1%
+95,000
New +$8.32M
TGTX icon
8
TG Therapeutics
TGTX
$8.53B
$11M 3.04%
1,366,062
+816,062
+148% +$4.41M
BOLD
9
DELISTED
Audentes Therapeutics, Inc
BOLD
$10.9M 3.03%
280,000
+30,000
+12% +$860K
KYNB
10
Kyntra Bio
KYNB
$32.4M
$10.9M 3.01%
8,000
– –
CMTA
11
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$10.4M 2.89%
400,130
+250,130
+167% +$4.67M
BPMC
12
DELISTED
Blueprint Medicines
BPMC
$10.4M 2.88%
130,000
-170,000
-57% -$12.6M
NVTA
13
DELISTED
Invitae Corporation
NVTA
$10.3M 2.85%
+440,000
New +$7.76M
CPRX
14
DELISTED
Catalyst Pharmaceutical
CPRX
$9.31M 2.58%
+1,825,000
New +$5.36M
HROW icon
15
Harrow
HROW
$1.44B
$8.96M 2.48%
1,800,000
+78,000
+5% +$472K
DNTH icon
16
Dianthus Therapeutics
DNTH
$6.24B
$8.4M 2.33%
31,875
+312
+1% +$53.8K
PTCT icon
17
PTC Therapeutics
PTCT
$5.99B
$8.05M 2.23%
213,800
+23,800
+13% +$799K
DCPH
18
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$7.89M 2.19%
340,000
– –
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7.7M 2.13%
+105,000
New +$7.14M
OCUL icon
20
Ocular Therapeutix
OCUL
$2.38B
$7.54M 2.09%
+1,900,000
New +$7.64M
CBAY
21
DELISTED
Cymabay Therapeutics
CBAY
$7.3M 2.02%
550,000
-175,000
-24% -$1.86M
ODT
22
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$7.19M 1.99%
325,000
+276,000
+563% +$4.83M
CYTK icon
23
Cytokinetics
CYTK
$10.8B
$6.88M 1.9%
+850,000
New +$6.25M
TCDA
24
DELISTED
Tricida, Inc. Common Stock
TCDA
$6.37M 1.76%
165,000
+42,000
+34% +$979K
ETON icon
25
Eton Pharmaceutcials
ETON
$1.79B
$6.12M 1.69%
764,773
+241,773
+46% +$1.68M
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2019 Portfolio in Review

As of Q1 2019, Opaleye Management held 67 positions worth $361M, up 35% from $268M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Opaleye Management's Q1 2019 filing shows 20 new, 17 increased, 12 reduced and 14 closed positions. Its largest new stake was uniQure: 205,000 shares worth $12.2M. The largest sale was Loxo Oncology, Inc, an estimated $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q1 2019 buy was uniQure: 205,000 shares worth $12.2M.
  • Opaleye Management added most to Odonate Therapeutics, Inc. Common Stock in Q1 2019, an estimated $4.83M increase.
  • Opaleye Management's biggest Q1 2019 reduction was Blueprint Medicines, cutting an estimated $12.6M.
  • Opaleye Management fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $24.5M.
  • Opaleye Management's ten largest holdings make up 42% of its $361M portfolio in Q1 2019.
  • Opaleye Management opened 20 new positions and closed 14 in Q1 2019.
  • Opaleye Management's portfolio value rose 35% quarter-over-quarter to $361M.

Based on Opaleye Management's 13F filing for Q1 2019, filed 15 May 2019.